“There was a point when people thought a trial [would] not be necessary because the answers [were] so clear cut. But obviously, more than just 1 person feels that these are not so clear-cut answers,” says Badar M. Mian, MD, FACS.
In this video, Badar M. Mian, MD, FACS, discusses what is to come for transperineal biopsy in regard to integrating this modality into the current standard of care for patients with prostate cancer. Mian is a professor of surgery and urology at Albany Med Urology in Albany, New York.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.